UA99259C2 - Лечение ожирения антагонистами мускаринового рецептора м1 - Google Patents

Лечение ожирения антагонистами мускаринового рецептора м1

Info

Publication number
UA99259C2
UA99259C2 UAA200900269A UAA200900269A UA99259C2 UA 99259 C2 UA99259 C2 UA 99259C2 UA A200900269 A UAA200900269 A UA A200900269A UA A200900269 A UAA200900269 A UA A200900269A UA 99259 C2 UA99259 C2 UA 99259C2
Authority
UA
Ukraine
Prior art keywords
mantagonist
acetylcholine receptor
muscarinic acetylcholine
treating obesity
antagonists
Prior art date
Application number
UAA200900269A
Other languages
English (en)
Ukrainian (uk)
Inventor
Брайан СИД
Джордан Мечаник
Original Assignee
Теракос, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Теракос, Инк. filed Critical Теракос, Инк.
Publication of UA99259C2 publication Critical patent/UA99259C2/ru

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины и касается способа содействия снижению массы тела или облегчения поддержания стабильной массы тела, который включает введение индивиду с ожирением или с чрезмерной массой тела телензепина и антидепрессанта, выбранного из группы, которая состоит из сертралина, циталопрама, эсциталопрама, венлафаксина и сибутрамина, в терапевтически эффективном количестве с целью снижения массы тела, благодаря чему активируется снижение массы тела или облегчается поддержание стабильной массы тела. Изобретение также касается фармацевтической композиции и набора.
UAA200900269A 2006-06-16 2007-06-15 Лечение ожирения антагонистами мускаринового рецептора м1 UA99259C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80506606P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
UA99259C2 true UA99259C2 (ru) 2012-08-10

Family

ID=40829458

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200900269A UA99259C2 (ru) 2006-06-16 2007-06-15 Лечение ожирения антагонистами мускаринового рецептора м1
UAA200900268A UA98938C2 (ru) 2006-06-16 2007-06-15 Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200900268A UA98938C2 (ru) 2006-06-16 2007-06-15 Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1

Country Status (2)

Country Link
CN (2) CN101472571B (ru)
UA (2) UA99259C2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
HUE070784T2 (hu) * 2010-10-25 2025-06-28 Univ Manitoba Terápiás készítmények diabéteszes szimmetrikus polineuropátia kezelésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
EP1520582A3 (en) * 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
WO2002022579A2 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
EP1369129A4 (en) * 2001-03-14 2005-08-03 Ono Pharmaceutical Co ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
WO2005101979A2 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management

Also Published As

Publication number Publication date
CN101472571A (zh) 2009-07-01
CN101472571B (zh) 2012-11-14
CN101472476B (zh) 2013-10-30
CN101472476A (zh) 2009-07-01
UA98938C2 (ru) 2012-07-10

Similar Documents

Publication Publication Date Title
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2008021368A3 (en) Compositions and methods for neuroprotection
MX2010002781A (es) Combinacion novedosa de angentes terapeuticos.
WO2007123984A3 (en) Pre-mixed, ready-to-use pharmaceutical compositions
LUC00077I2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2007098113A3 (en) Ccr3 inhibition for ocular angiogenesis and macular degeneration
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
WO2006055752A3 (en) INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
PT2061561E (pt) Composições para tratar o cancro
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2005051297A3 (en) Combination drug therapy to treat obesity
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
NZ588913A (en) Liver cancer drug
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2006135638A3 (en) Tanaproget compositions containing ethinyl estradiol